Investors Hangout Stock Message Boards Logo
  • Home
  • Mailbox
  • Boards
  • Favorites
  • Whats Hot!
  • Login - Join Now!
CytoDyn Inc CYDY
(Total Views: 687)
Posted On: 11/09/2021 7:38:37 PM
Post# of 155161
Posted By: crazyjogger925
Re: nmbr1stckpckr #110210
a pattern ive noticed usually remdesivir first maybe next tocilizumab followed by a few others usually for severe cases.then when all else fails maybe the patient gets LL IF LUCKY ?


check out the trodelvy pricing immunomedics set up for tnbc back in april 2020 and pretty much in line with the gilead pricing today.makes leronlimab the bargain of the century.imo

Immunomedics Inc. shares (NASDAQ:IMMU) were trading at $26.96, up $4.99, or 22%, on the approval yesterday of the antibody-drug conjugate Trodelvy (sacituzumab govitecan-hziy) to treat metastatic triple-negative breast cancer. Trodelvy, to be launched soon, was cleared for patients who have undergone at least two prior therapies. Morris Plains, N.J.-based Immunomedics set the wholesale acquisition cost for a single-use 180-mg vial at $2,012, which equates to $16,096 per 21-day cycle for a 70-kg person. Officials outlined marketing plans during a conference call with investor

https://www.goodrx.com/trodelvy














(3)
(0)









  • New Post - Investors HangoutNew Post

  • Public Reply - Investors HangoutPublic Reply

  • Private Reply - Investors HangoutPrivate Reply

  • Board - Investors HangoutBoard

  • More - Investors HangoutMore

  • Keep Post - Investors HangoutKeep Post
  • Report Post - Investors HangoutReport Post
  • Home - Investors HangoutHome
  • Mailbox - Investors HangoutMailbox
  • Boards - Investors HangoutBoards
  • Favorites - Investors HangoutFavorites
  • Whats Hot! - Investors HangoutWhats Hot!
  • Settings - Investors HangoutSettings
  • Login - Investors HangoutLogin
  • Live Site - Investors HangoutLive Site